| Bioactivity | VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110[1]. | ||||||||||||
| Name | VEGFR-2-IN-6 | ||||||||||||
| CAS | 444731-47-9 | ||||||||||||
| Formula | C20H21N7O2S | ||||||||||||
| Molar Mass | 423.49 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Glaxo Wellcome House, et al. PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS. Patent WO 02/059110. |
VEGFR-2-IN-6
CAS: 444731-47-9 F: C20H21N7O2S W: 423.49
VEGFR-2-IN-6 (example 64) is a VEGFR2 inhibitor (angiogenesis modulator), which is extracted from patent WO 02/059110.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.